研究文章
协会的心肌酶异常患者的临床结果COVID-19:一项回顾性研究
|
|
(总
) |
与心肌损伤(
) |
没有心肌损伤(
) |
|
价值 |
|
| 年龄、中值(范围),y |
54 (36 - 66) |
66 (56.5 -78) |
48 (35 - 64) |
-3.502 |
< 0.001 |
| 性别(男性) |
44 (57.9%) |
12 (66.7%) |
32 (55.2%) |
0.745 |
0.388 |
| 发烧 |
54 (71.1%) |
9 (50.0%) |
45 (77.6%) |
5.083 |
0.024 |
| 咳嗽 |
42 (55.3%) |
9 (50.0%) |
33 (56.9%) |
0.264 |
0.607 |
| 胸痛/紧张 |
32 (42.1%) |
7 (38.9%) |
25 (43.1%) |
0.1 |
0.752 |
| 呼吸速率 |
21日(3.39) |
22.3 (4.36) |
20.7 (3.02) |
|
0.09 |
| 收缩压,毫米汞柱 |
128年(117 - 138) |
124年(101 - 140) |
130 (118.75 -138) |
-1.517 |
0.129 |
| 舒张压,毫米汞柱 |
80年(73 - 89) |
75 (65.5 -90) |
80年(76 - 89) |
-1.646 |
0.1 |
| 高血压 |
25 (32.9%) |
6 (33.3%) |
19 (32.8%) |
0.002 |
0.964 |
| 糖尿病 |
11 (14.5%) |
3 (16.7%) |
8 (13.8%) |
0.092 |
0.762 |
| 心血管和脑血管疾病 |
15 (19.7%) |
7 (38.9%) |
8 (13.8%) |
5.461 |
0.019 |
| 慢性肺疾病 |
6 (7.9%) |
4 (22.2%) |
2 (3.4%) |
6.658 |
0.01 |
| 有超过两个并发症 |
15 (19.7%) |
5 (27.8%) |
10 (17.2%) |
0.963 |
0.327 |
| 严重的 |
31 (40.8%) |
13 (72.2%) |
18 (31.0%) |
9.649 |
0.002 |
| 常见的 |
45 (73.2%) |
5 (27.8%) |
40 (69.0%) |
| 死亡 |
15 (19.7%) |
11 (61.1%) |
4 (6.9%) |
25.487 |
< 0.001 |
| 放电 |
59 (77.6%) |
6 (33.3%) |
53 (91.4%) |
|
|
提出了连续变量的意思(标准偏差(SD))。其他连续变量作为中位数(四分位范围(差))。
|
